Trial Profile
A randomized, placebo-controlled, double-blind Phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of R835 in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jun 2020
Price :
$35
*
At a glance
- Drugs R 835 Rigel Pharmaceuticals (Primary) ; Lipopolysaccharide
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 03 Jun 2020 According to a Rigel Pharmaceuticals media release, data from this study will be presented at the European League Against Rheumatism (EULAR) 2020 E-Congress taking place June 3-6, 2020.
- 03 Jun 2020 Results published in the Rigel Pharmaceuticals media release